Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis

Gut

Volumn 66, Issue 1, 2015, Pages 145-155

  Klein, Sabine ^a   Rick, Johanna ^a   Lehmann, Jennifer ^a   Schierwagen, Robert ^a   Schierwagen, Irela Gretchen ^a   Verbeke, Len ^b   Hittatiya, Kanishka ^a   Uschner, Frank Erhard ^a   Manekeller, Steffen ^a   Strassburg, Christian P ^a   Wagner, Kay Uwe ^c   Sayeski, Peter P ^d   Wolf, Dominik ^a   Wim Laleman, ^b   Sauerbruch, Tilman ^a   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PEPTIDES AND PROTEINS; PROTEIN ARHGEF1; PROTEIN ROCK; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CARBON TETRACHLORIDE; COLLAGEN; ENZYME INHIBITOR; MESSENGER RNA; MUSCLE PROTEIN; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSGELIN; TYRPHOSTIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARHGEF1 GENE; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; END STAGE LIVER DISEASE; FEMALE; GENETIC TRANSCRIPTION; HEPATIC STELLATE CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; JAK2 GENE; LIVER CIRRHOSIS; MALE; MYOFIBROBLAST; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VARICOSIS; VASCULAR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIGATION; METABOLISM; MIDDLE AGED; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SPRAGUE DAWLEY RAT; UPREGULATION; YOUNG ADULT;

ADULT; ANIMALS; CARBON TETRACHLORIDE; COLLAGEN; ENZYME INHIBITORS; FEMALE; HEPATIC STELLATE CELLS; HUMANS; HYPERTENSION, PORTAL; JANUS KINASE 2; LIGATION; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; MYOFIBROBLASTS; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TYRPHOSTINS; UP-REGULATION; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84942134764     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309600     Document Type: Article

References (36)

1. World Health Organisation. The World Health report 2002: reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organisation, 2002:1-230
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18
3. Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis-A guess. F1000 Prime Rep 2014;6:95
4. Hennenberg M, Trebicka J, Sauerbruch T, et al. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-14
5. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69
6. Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823
7. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56
8. Heller J, Shiozawa T, Trebicka J, et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006-12
9. Heller J, Trebicka J, Shiozawa T, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 2005;25:657-66
10. Granzow M, Schierwagen R, Klein S, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014;60:334-48
11. Guilluy C, Bregeon J, Toumaniantz G, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 2010;16:183-90
12. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53
13. Trebicka J, Hennenberg M, Schulze Probsting A, et al. Role of beta3-Adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 2009;50:1924-35
14. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells J Hepatol 2010;53:702-12
15. Klein S, Van Beuge MM, Granzow M, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-7
16. Marrone G, Maeso-Diaz R, Garcia-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 2015;64:1434-43
17. Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut 2015;64:1349-50
18. Wang D, Yin J, Dong R, et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. Dig Liver Dis 2015;47:315-23
19. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats Gastroenterology 2006;130:838-54
20. Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007;45:495-506
21. Domenicali M, Caraceni P, Giannone F, et al. A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol 2009;51:991-9
22. Moleda L, Trebicka J, Dietrich P, et al. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011;60:1122-32
23. Trebicka J, Leifeld L, Hennenberg M, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008;47:1264-76
24. Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-Angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 2013;145:874-84.e5
25. Ma TK, Kam KK, Yan BP, et al. Renin-Angiotensin-Aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92
26. Wolf G. Novel aspects of the renin-Angiotensin-Aldosterone-system. Front Biosci 2008;13:4993-5005
27. Uhal BD, Li X, Piasecki CC, et al. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol 2012;44:465-8
28. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94
29. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension J Hepatol 2000;32(Suppl 1):141-56
30. Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-9
31. Feng J, Witthuhn BA, Matsuda T, et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997;17:2497-501
32. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901
33. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-305
34. Laleman W, Van Landeghem L, Severi T, et al. Both Ca2+-dependent and-independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-64
35. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
36. LaFave LM, Levine RL. JAK2 the future: Therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci 2012;33:574-82